icon flag insights

Characterization of drug conjugates

Characterize and compare binding of your drug conjugates

Antibody drug conjugates, radiotracers and radioimmunotherapy all rely on the incorporation of a secondary molecule or nuclide to the original ligand. LigandTracer enables a detailed investigation of possible conjugation effects and helps you choose the best alternative.

lt-icon-instrument_white
lt-icon-instrument_grey
lt-icon-instrument-yellow-01
lt-icon-instrument-green
Click images to enlarge
A Fab fragment under development for imaging was labeled with 125I and 111In and added to A431 cells as monolayers in LigandTracer (in vitro) or as tumor xenografts in mice (in vivo). A significantly higher retention of 111In-Fab was observed both in vitro and in vivo.

Gained information

  • How conjugations affect the affinity
  • How conjugations affect the binding kinetics
  • in vitro predictions of radiotracers
  • Possible variations in binding mode
  • Batch-to-batch variation
  • Ligand heterogeneity

Resources



Publications

Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging.
Honarvar H, Jokilaakso N, Andersson K, Malmberg J, Rosik D, Orlova A, Karlström AE, Tolmachev V, Järver P.
Nucl Med Biol. 2013. 40(3):378-386.
PubMed

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Mortensen AC, Spiegelberg D, Haylock AK, Lundqvist H, Nestor M.
Int J Oncol. 2018. 52(6):1875-1885.
PubMed